StockNews.com Begins Coverage on Genocea Biosciences (NASDAQ:GNCA)

Equities research analysts at StockNews.com started coverage on shares of Genocea Biosciences (NASDAQ:GNCAGet Rating) in a research report issued to clients and investors on Tuesday. The firm set a “sell” rating on the biotechnology company’s stock.

Genocea Biosciences Stock Performance

The company has a debt-to-equity ratio of 0.24, a quick ratio of 1.35 and a current ratio of 1.35. The firm has a market capitalization of $6,000.00, a P/E ratio of 0.00 and a beta of 1.61. Genocea Biosciences has a 52 week low of $0.00 and a 52 week high of $0.00. The business’s 50 day simple moving average is $0.01 and its 200-day simple moving average is $0.01.

About Genocea Biosciences

(Get Rating)

Genocea Biosciences, Inc, a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor.

Recommended Stories

Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.